Omnicell Cash Flow Statement
OMCL / Health Care|15 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 15 fiscal years. All figures from audited SEC 10-K filings.
Omnicell generated $127M in operating cash flow and $87M in free cash flow in FY2025. Free cash flow margin was 7.3% of revenue.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $2.1M | $12.5M | -$20.4M | $5.6M | $77.8M | $32.2M | $61.3M | $37.7M | $30.5M | $30.5M | $30.8M | $30.5M | $10.4M | $16.2M | $10.4M |
| Depreciation & Amortization | $78.8M | $82.2M | $87.3M | $86.9M | $73.0M | $61.1M | $53.6M | $51.4M | $51.5M | $20.3M | $25.6M | $20.3M | $8.0M | $13.3M | $8.0M |
| Operating Cash Flow | $127.3M | $187.7M | $181.1M | $77.8M | $231.8M | $185.9M | $145.0M | $104.0M | $24.8M | $65.2M | $38.5M | $65.2M | $31.2M | $39.5M | $31.2M |
| Capital Expenditures | $40.4M | $36.5M | $41.5M | $47.5M | $29.0M | $22.8M | $15.9M | $23.7M | $15.3M | $11.9M | $7.5M | $11.9M | $8.7M | $15.1M | $8.7M |
| Free Cash Flow | $86.9M | $151.3M | $139.6M | $30.2M | $202.8M | $163.0M | $129.1M | $80.3M | $9.5M | $53.2M | $30.9M | $53.2M | $22.6M | $24.4M | $22.6M |
| Share Buybacks | $77.6M | $0 | $0 | $52.2M | $0 | $53.0M | $0 | $0 | $0 | $24.1M | $50.0M | $24.1M | $12.6M | $12.4M | $12.6M |
| FCF Margin | 7.3% | 13.6% | 12.2% | 2.3% | 17.9% | 18.3% | 14.4% | 10.2% | 1.3% | 12.1% | 6.4% | 12.1% | 9.2% | 7.8% | 9.2% |